Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine Publisher Pubmed



Mahmoudi H1 ; Ebrahimi E1 ; Daneshpazhooh M1 ; Balighi K1 ; Mirzazadeh A2 ; Elikaei Behjati S1 ; Tavakolpour S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Joint Bioinformatics graduate Program, University of Arkansas Little Rock and University of Arkansas for Medical Sciences, Little Rock, AR, United States

Source: International Journal of Immunogenetics Published:2020


Abstract

Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder, which could affect both skin and mucosal surfaces. There is increasing evidence that genetics plays a critical role in PV development, severity and prognosis. Single-nucleotide polymorphisms (SNPs) are the most common type of genetic variation among people and have been widely evaluated in most diseases. However, there are few studies regarding the roles of SNPs in the PV. Here, we reviewed both pathogenic and protective roles of the SNPs in non-HLA genes regarding the PV. Among the large number of studied SNPs, it was found that several SNPs in different genes might control the susceptibility of PV, including TNFA (rs361525, rs1800629, rs1800629), IL10 (rs1800871, rs1800896, rs1800871, and rs1800872), IL6 (rs1800795), CTLA4 (rs231775), ICOS (rs10932029), CD86 (rs1129055), DSG3 (rs8085532, rs3911655, rs3848485, rs3794925, rs1466379), ST18 (rs2304365, rs17315309) and TAP2 (rs7454108), probably in a population-specific manner. Moreover, SNPs in glucocorticoid receptor, also known as nuclear receptor subfamily 3 group C member 1 (NR3C1) gene, including rs11745958, rs17209237, rs33388, rs7701443 as well as rs116855232 at NUDT15, seem to be associated with therapeutic outcomes in PV patients. Additionally, variations in the other genes involved in the drugs' metabolisms, pharmacokinetics and pharmacodynamics such as rs396991 in FCGR3A gene could be used for the prediction of clinical response to drugs and side effects. Taken together, SNPs seem to be valuable tools for better management of PV patients. Further studies need to be conducted to evaluate SNPs in genes that control immune responses and apoptosis. © 2019 John Wiley & Sons Ltd
Related Docs
View other Related Docs
1. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
2. What Is Novel in the Clinical Management of Pemphigus Vulgaris?, Expert Review of Clinical Pharmacology (2024)
3. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
4. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
5. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)
6. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
7. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
8. Genetic Predisposition to Ocular Surface Disorders and Opportunities for Gene-Based Therapies, Ocular Surface (2023)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (30)
Hamid Reza Mahmoodi (22)
Other Related Docs
9. Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases, International Immunopharmacology (2019)
10. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
11. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)
12. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
13. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
14. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
15. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
16. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
17. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
18. Covid-19: The Experience From Iran, Clinics in Dermatology (2021)
19. Interleukin 4 Inhibition As a Potential Therapeutic in Pemphigus, Cytokine (2016)
20. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
21. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
22. Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, But Not Chronic Patients With Inactive Disease Compared to Healthy Controls, Dermatology Practical and Conceptual (2021)
23. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
24. Comparison of Topical Nanocolloidal Silver Formulation Use With Eosin 2% Solution in Management of Hard-To-Heal Ulcers in Patients With Pemphigus Vulgaris, Journal of Wound Care (2020)
25. De Novo Severe Pemphigus Vulgaris Following Sars-Cov-2 Vaccination With Bbibp-Corv, Dermatologic Therapy (2022)
26. Expression of Human Endogenous Retroviruses in Pemphigus Vulgaris Patients, Molecular Biology Reports (2019)
27. Trauma-Induced Pemphigus: A Case Series of 36 Patients; [Trauma-Induzierter Pemphigus: Eine Fallserie Von 36 Patienten], JDDG - Journal of the German Society of Dermatology (2016)
28. The Dual Nature of Retinoic Acid in Pemphigus and Its Therapeutic Potential: Special Focus on All-Trans Retinoic Acid, International Immunopharmacology (2016)
29. The Possible Role of Interleukin-35 and Its Therapeutic Potential in Pemphigus, International Immunopharmacology (2017)
30. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
31. High Dietary Acid Load Predicts Severity of Autoimmune Skin Disease: A Cross-Sectional Study, Scientific Reports (2024)
32. Evaluation of Autoimmune Bullous Diseases in Elderly Patients in Iran: A 10-Year Retrospective Study, SKINmed (2017)
33. Neurological Diseases and Bullous Pemphigoid: A Case-Control Study in Iranian Patients, Indian Journal of Dermatology# Venereology and Leprology (2017)
34. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
35. A Comprehensive Review of Rituximab Therapy in Rheumatoid Arthritis Patients, Clinical Rheumatology (2019)
36. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
37. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
38. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)
39. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
40. Association of Alternative Healthy Eating Index and Severity of Pemphigus Vulgaris: A Crosssectional Study, PLoS ONE (2023)